Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Legend Biotech (LEGN) EBITDA Margin (2019 - 2025)

Historic EBITDA Margin for Legend Biotech (LEGN) over the last 7 years, with Q3 2025 value amounting to 14.9%.

  • Legend Biotech's EBITDA Margin fell 246900.0% to 14.9% in Q3 2025 from the same period last year, while for Sep 2025 it was 73.54%, marking a year-over-year increase of 162600.0%. This contributed to the annual value of 23412.57% for FY2024, which is 95085900.0% up from last year.
  • According to the latest figures from Q3 2025, Legend Biotech's EBITDA Margin is 14.9%, which was down 246900.0% from 0.46% recorded in Q2 2025.
  • In the past 5 years, Legend Biotech's EBITDA Margin ranged from a high of 395.35% in Q4 2022 and a low of 1515.42% during Q2 2022
  • Moreover, its 5-year median value for EBITDA Margin was 77.49% (2022), whereas its average is 187.18%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first crashed by -10576100bps in 2022, then skyrocketed by 12343700bps in 2023.
  • Legend Biotech's EBITDA Margin (Quarter) stood at 230.36% in 2021, then soared by 72bps to 395.35% in 2022, then crashed by -85bps to 57.62% in 2023, then increased by 28bps to 73.77% in 2024, then crashed by -80bps to 14.9% in 2025.
  • Its EBITDA Margin stands at 14.9% for Q3 2025, versus 0.46% for Q2 2025 and 31.13% for Q1 2025.